D-0233-2024 Class I Ongoing

Recalled by Pfizer Inc. — New York, NY

FDA drug recall D-0233-2024 was initiated by Pfizer Inc. on Dec 21, 2023 and is designated Class I. Reason for recall: Presence of Particulate Matter; identified as glass The recall status is ongoing. Affected quantity: 34000 Cartons.

Recall details

Product Type
Drugs
Report Date
Jan 24, 2024
Initiation Date
Dec 21, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
34000 Cartons

Product description

4.2% Sodium Bicarbonate Injection, USP 5 mEq/10 mL (0.5 mEq/mL), Glass ABBOJECT Unit of Use Syringe, For Intravenous Use, Rx Only, 10 mL Syringe per Carton, Hospira, Inc., Lake Forst, IL 60045, NDC 0409-5534-24 (carton), 0409-5534-14 (case).

Reason for recall

Presence of Particulate Matter; identified as glass

Distribution pattern

Nationwide in the USA and Puerto Rico.

Code information

Lot GX1542, Exp. 01/01/2025

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0233-2024
openFDA file date
Nov 19, 2026
Loaded by RegDataLab
Nov 20, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Need the full FDA record for Pfizer Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: openFDA record for D-0233-2024. Report a data issue: hello@regdatalab.com.